Skip to main content
Top
Published in: BMC Health Services Research 1/2022

Open Access 01-12-2022 | COVID-19 | Research

A strategy to identify event specific hospitalizations in large health claims databases

Authors: Joshua Lambert, Harpal Sandhu, Emily Kean, Teenu Xavier, Aviv Brokman, Zachary Steckler, Lee Park, Arnold Stromberg

Published in: BMC Health Services Research | Issue 1/2022

Login to get access

Abstract

Background

Health insurance claims data offer a unique opportunity to study disease distribution on a large scale. Challenges arise in the process of accurately analyzing these raw data. One important challenge to overcome is the accurate classification of study outcomes. For example, using claims data, there is no clear way of classifying hospitalizations due to a specific event. This is because of the inherent disjointedness and lack of context that typically come with raw claims data.

Methods

In this paper, we propose a framework for classifying hospitalizations due to a specific event. We then tested this framework in a private health insurance claims database (Symphony) with approximately 4 million US adults who tested positive with COVID-19 between March and December 2020. Our claims specific COVID-19 related hospitalizations proportion is then compared to nationally reported rates from the Centers for Disease Control by age.

Results

Across all ages (18 +) the total percentage of Symphony patients who met our definition of hospitalized due to COVID-19 was 7.3% which was similar to the CDC’s estimate of 7.5%. By age group, defined by the CDC, our estimates vs. the CDC’s estimates were 18–49: 2.7% vs. 3%, 50–64: 8.2% vs. 9.2%, and 65 + : 14.6% vs. 28.1%.

Conclusions

The proposed methodology is a rigorous way to define event specific hospitalizations in claims data. This methodology can be extended to many different types of events and used on a variety of different types of claims databases.
Literature
1.
go back to reference Konrad R, Zhang W, Bjarndóttir M, Proaño R. Key considerations when using health insurance claims data in advanced data analyses: an experience report. Health Syst (Basingstoke). 2019;9(4):317–25.CrossRef Konrad R, Zhang W, Bjarndóttir M, Proaño R. Key considerations when using health insurance claims data in advanced data analyses: an experience report. Health Syst (Basingstoke). 2019;9(4):317–25.CrossRef
2.
go back to reference Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25(7):770–9.PubMed Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25(7):770–9.PubMed
3.
go back to reference Ash A, Porell F, Gruenberg L, Sawitz E, Beiser A. Adjusting Medicare capitation payments using prior hospitalization data. Health Care Financ Rev. 1989;10(4):17–29.PubMedPubMedCentral Ash A, Porell F, Gruenberg L, Sawitz E, Beiser A. Adjusting Medicare capitation payments using prior hospitalization data. Health Care Financ Rev. 1989;10(4):17–29.PubMedPubMedCentral
4.
go back to reference Biskupiak J, Oderda G, Brixner D, Tang D, Zacker C, Dalal AA. Quantification of economic impact of drug wastage in oral oncology medications: comparison of 3 methods using palbociclib and ribociclib in advanced or metastatic breast cancer. J Manag Care Spec Pharm. 2019;25(8):859–66.PubMed Biskupiak J, Oderda G, Brixner D, Tang D, Zacker C, Dalal AA. Quantification of economic impact of drug wastage in oral oncology medications: comparison of 3 methods using palbociclib and ribociclib in advanced or metastatic breast cancer. J Manag Care Spec Pharm. 2019;25(8):859–66.PubMed
5.
go back to reference Chan SS, Chappel AR, Maddox KEJ, Hoover KW, Huang Y-LA, Zhu W, et al. Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015–2016. PLoS Med. 2020;17(4):e1003072.CrossRefPubMedCentral Chan SS, Chappel AR, Maddox KEJ, Hoover KW, Huang Y-LA, Zhu W, et al. Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015–2016. PLoS Med. 2020;17(4):e1003072.CrossRefPubMedCentral
6.
go back to reference Dellay B, Sexter A, Wang JH, Hess GP, Ray Kim W, Israni AK. Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection. Pharmacotherapy. 2019;39(4):424–32.CrossRef Dellay B, Sexter A, Wang JH, Hess GP, Ray Kim W, Israni AK. Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection. Pharmacotherapy. 2019;39(4):424–32.CrossRef
7.
go back to reference Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care. 2014;37(5):1367–74.CrossRef Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care. 2014;37(5):1367–74.CrossRef
8.
go back to reference Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing. Circulation. 2017;136(23):2210–9.CrossRefPubMedCentral Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing. Circulation. 2017;136(23):2210–9.CrossRefPubMedCentral
9.
go back to reference Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30(7):1317–25.CrossRef Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30(7):1317–25.CrossRef
10.
go back to reference Lam NN, Schnitzler MA, Segev DL, Hess GP, Kasiske BL, Randall HB, et al. Diabetes mellitus in living pancreas donors: use of integrated national registry and pharmacy claims data to characterize donation-related health outcomes. Transplantation. 2017;101(6):1276–81.CrossRefPubMedCentral Lam NN, Schnitzler MA, Segev DL, Hess GP, Kasiske BL, Randall HB, et al. Diabetes mellitus in living pancreas donors: use of integrated national registry and pharmacy claims data to characterize donation-related health outcomes. Transplantation. 2017;101(6):1276–81.CrossRefPubMedCentral
11.
go back to reference Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the united states. Am J Cardiol. 2016;117(10):1651–4.CrossRef Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the united states. Am J Cardiol. 2016;117(10):1651–4.CrossRef
12.
go back to reference Miller C, Apple S, Paige JS, Grabowsky T, Shukla O, Agnese W, et al. Current and future projections of amyotrophic lateral sclerosis in the united states using administrative claims data. Neuroepidemiology. 2021;55(4):275–85.CrossRef Miller C, Apple S, Paige JS, Grabowsky T, Shukla O, Agnese W, et al. Current and future projections of amyotrophic lateral sclerosis in the united states using administrative claims data. Neuroepidemiology. 2021;55(4):275–85.CrossRef
13.
go back to reference Myung G, Nelson WW, McMahon MA. Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: A claims data study. Journal of Pharmacy Technology. 2017;33(4):151–5.CrossRef Myung G, Nelson WW, McMahon MA. Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: A claims data study. Journal of Pharmacy Technology. 2017;33(4):151–5.CrossRef
14.
go back to reference Null K, Kumar V, Lissoos T, Luo M. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease. J Med Econ. 2018;21(11):1102–9.CrossRef Null K, Kumar V, Lissoos T, Luo M. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease. J Med Econ. 2018;21(11):1102–9.CrossRef
15.
go back to reference Parks MM, Secemsky EA, Yeh RW, Shen C, Choi E, Kazi DS, et al. Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. Eur Heart J Qual Care Clin Outcomes. 2021;7(3):273–9.CrossRef Parks MM, Secemsky EA, Yeh RW, Shen C, Choi E, Kazi DS, et al. Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. Eur Heart J Qual Care Clin Outcomes. 2021;7(3):273–9.CrossRef
16.
go back to reference Randall HB, Alhamad T, Schnitzler MA, Zhang Z, Ford-Glanton S, Axelrod DA, et al. Survival implications of opioid use before and after liver transplantation. Liver Transpl. 2017;23(3):305–14.CrossRef Randall HB, Alhamad T, Schnitzler MA, Zhang Z, Ford-Glanton S, Axelrod DA, et al. Survival implications of opioid use before and after liver transplantation. Liver Transpl. 2017;23(3):305–14.CrossRef
17.
go back to reference Rice JB, Panaccio MP, White A, Simes M, Billmyer E, Downes N, et al. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome. Curr Med Res Opin. 2021;37(3):431–41.CrossRef Rice JB, Panaccio MP, White A, Simes M, Billmyer E, Downes N, et al. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome. Curr Med Res Opin. 2021;37(3):431–41.CrossRef
18.
go back to reference Rohr MK, Mikuls TR, Cohen SB, Thorne JC, O’Dell JR. Underuse of methotrexate in the treatment of rheumatoid arthritis: A national analysis of prescribing practices in the US. Arthritis Care Res (Hoboken). 2017;69(6):794–800.CrossRef Rohr MK, Mikuls TR, Cohen SB, Thorne JC, O’Dell JR. Underuse of methotrexate in the treatment of rheumatoid arthritis: A national analysis of prescribing practices in the US. Arthritis Care Res (Hoboken). 2017;69(6):794–800.CrossRef
19.
go back to reference Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018;1(189):37–41.CrossRef Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018;1(189):37–41.CrossRef
20.
go back to reference Tang Y, Huang X, Liu J, Shankar RR, Ganz ML, Rajpathak S. The effects of a sitagliptin formulary restriction program on diabetes medication use. Am Health Drug Benefits. 2017;10(9):456–62.PubMedPubMedCentral Tang Y, Huang X, Liu J, Shankar RR, Ganz ML, Rajpathak S. The effects of a sitagliptin formulary restriction program on diabetes medication use. Am Health Drug Benefits. 2017;10(9):456–62.PubMedPubMedCentral
21.
go back to reference Zhang KH, Singh H, Twardowski R, Lu C, Wan Y, Null K. Pgi4 retrospective study of dose escalation with adalimumab, infliximab, and vedolizumab in the treatment of inflammatory bowel disease. Value Health. 2020;23:S143.CrossRef Zhang KH, Singh H, Twardowski R, Lu C, Wan Y, Null K. Pgi4 retrospective study of dose escalation with adalimumab, infliximab, and vedolizumab in the treatment of inflammatory bowel disease. Value Health. 2020;23:S143.CrossRef
22.
go back to reference Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935–44.CrossRef Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935–44.CrossRef
23.
go back to reference Joshi K, Lafeuille M-H, Brown B, Wynant W, Emond B, Lefebvre P, et al. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. Curr Med Res Opin. 2017;33(10):1763–72.CrossRef Joshi K, Lafeuille M-H, Brown B, Wynant W, Emond B, Lefebvre P, et al. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. Curr Med Res Opin. 2017;33(10):1763–72.CrossRef
24.
go back to reference Lee J, Pelkey R, Gubitosa J, Henrick MF, Ganz ML. Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States. Am Health Drug Benefits. 2017;10(1):42–9.PubMedPubMedCentral Lee J, Pelkey R, Gubitosa J, Henrick MF, Ganz ML. Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States. Am Health Drug Benefits. 2017;10(1):42–9.PubMedPubMedCentral
25.
go back to reference Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, et al. Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib. Clin Colorectal Cancer. 2018;17(3):e531–9.CrossRef Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, et al. Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib. Clin Colorectal Cancer. 2018;17(3):e531–9.CrossRef
26.
go back to reference Pergolizzi JV, Ben-Joseph R, Chang C-L, Hess G. Predicting medication persistence to buprenorphine transdermal system. Pain Pract. 2015;15(2):140–9.CrossRef Pergolizzi JV, Ben-Joseph R, Chang C-L, Hess G. Predicting medication persistence to buprenorphine transdermal system. Pain Pract. 2015;15(2):140–9.CrossRef
27.
go back to reference Rymer JA, Fonseca E, Bhandary DD, Kumar D, Khan ND, Wang TY. Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction. J Am Heart Assoc. 2021;10(1): e016215.CrossRef Rymer JA, Fonseca E, Bhandary DD, Kumar D, Khan ND, Wang TY. Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction. J Am Heart Assoc. 2021;10(1): e016215.CrossRef
28.
go back to reference Emond B, Rossi C, Côté-Sergent A, Dunn K, Lefebvre P, Lafeuille M-H, et al. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. J Health Econ Outcomes Res. 2021;8(1):88–98.CrossRefPubMedCentral Emond B, Rossi C, Côté-Sergent A, Dunn K, Lefebvre P, Lafeuille M-H, et al. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. J Health Econ Outcomes Res. 2021;8(1):88–98.CrossRefPubMedCentral
29.
go back to reference Lentine KL, Lam NN, Schnitzler MA, Hess GP, Kasiske BL, Xiao H, et al. Predonation prescription opioid use: A novel risk factor for readmission after living kidney donation. Am J Transplant. 2017;17(3):744–53.CrossRef Lentine KL, Lam NN, Schnitzler MA, Hess GP, Kasiske BL, Xiao H, et al. Predonation prescription opioid use: A novel risk factor for readmission after living kidney donation. Am J Transplant. 2017;17(3):744–53.CrossRef
30.
go back to reference Matias G, Haguinet F, Lustig RL, Edelman L, Chowell G, Taylor RJ. Model estimates of the burden of outpatient visits attributable to influenza in the United States. BMC Infect Dis. 2016;16(1):641.CrossRefPubMedCentral Matias G, Haguinet F, Lustig RL, Edelman L, Chowell G, Taylor RJ. Model estimates of the burden of outpatient visits attributable to influenza in the United States. BMC Infect Dis. 2016;16(1):641.CrossRefPubMedCentral
31.
go back to reference Mehta D, Davis M, Epstein AJ, Wensel B, Grinnell T, Williams GR. Impact of early initiation of eslicarbazepine acetate on economic outcomes among patients with focal seizure: results from retrospective database analyses. Neurol Ther. 2020;9(2):585–98.CrossRefPubMedCentral Mehta D, Davis M, Epstein AJ, Wensel B, Grinnell T, Williams GR. Impact of early initiation of eslicarbazepine acetate on economic outcomes among patients with focal seizure: results from retrospective database analyses. Neurol Ther. 2020;9(2):585–98.CrossRefPubMedCentral
32.
go back to reference Potnis A, VanMeter S, Stange J. Prevalence of Hepatic Encephalopathy from a Commercial Medical Claims Database in the United States. Int J Hepatol. 2021;8(2021):8542179. Potnis A, VanMeter S, Stange J. Prevalence of Hepatic Encephalopathy from a Commercial Medical Claims Database in the United States. Int J Hepatol. 2021;8(2021):8542179.
33.
go back to reference Ryan KJ, Nero D, Feinberg BA, Lee CH, Pimentel R, Gajra A, et al. Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer. Future Oncol. 2020;16(1):4303–13.CrossRef Ryan KJ, Nero D, Feinberg BA, Lee CH, Pimentel R, Gajra A, et al. Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer. Future Oncol. 2020;16(1):4303–13.CrossRef
34.
go back to reference Song Y, Betts KA, Lu Y, Singh R, Clewell J, Griffith J. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis. Rheumatol Ther. 2019;6(2):285–97.CrossRefPubMedCentral Song Y, Betts KA, Lu Y, Singh R, Clewell J, Griffith J. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis. Rheumatol Ther. 2019;6(2):285–97.CrossRefPubMedCentral
Metadata
Title
A strategy to identify event specific hospitalizations in large health claims databases
Authors
Joshua Lambert
Harpal Sandhu
Emily Kean
Teenu Xavier
Aviv Brokman
Zachary Steckler
Lee Park
Arnold Stromberg
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
COVID-19
Published in
BMC Health Services Research / Issue 1/2022
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-022-08107-x

Other articles of this Issue 1/2022

BMC Health Services Research 1/2022 Go to the issue